NCT05324163View on ClinicalTrials.gov

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

February 6, 2023

Conditions
KNEE OSTEOARTHRITIS
Interventions
DRUG

X0002 Spray

X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day

DRUG

Celecoxib capsules

X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day

DRUG

placebo

X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day

Trial Locations (1)

100005

China,Beijing, Beijing

All Listed Sponsors
lead

Jiangsu XinChen-Techfields Pharma Co., LTD.

INDUSTRY

NCT05324163 - Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis | Biotech Hunter | Biotech Hunter